Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lessened its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 29.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 839,131 shares of the biopharmaceutical company’s stock after selling 350,869 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.64% of Dynavax Technologies worth $10,716,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Norges Bank acquired a new stake in Dynavax Technologies in the 4th quarter worth approximately $7,762,000. WINTON GROUP Ltd raised its holdings in shares of Dynavax Technologies by 339.0% in the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 329,579 shares during the last quarter. Trexquant Investment LP lifted its stake in shares of Dynavax Technologies by 48.7% during the fourth quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company’s stock worth $9,915,000 after buying an additional 254,405 shares during the period. Nordea Investment Management AB grew its holdings in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after buying an additional 232,690 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 175,118 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on DVAX. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Down 1.6 %

Dynavax Technologies stock opened at $12.65 on Friday. The business’s 50-day moving average price is $13.37 and its 200 day moving average price is $12.55. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 70.28 and a beta of 1.23. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. As a group, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.